Blocking ALOX5/LTA4H in macrophages may prevent TB lung damage

Tuberculosis remains one of the major global health challenges, and people who have had TB often continue to live with lasting lung problems. Those previously exposed to the disease can present persisting pulmonary dysfunction, so researchers are looking for ways not only to kill the bacteria but also to prevent the immune system from causing long-term damage. Host directed therapies that target host factors have been proposed as a way to improve outcomes. Building on earlier work that identified a possible role for proteins that metabolize arachidonic acids, the team led by Mohlopheni J. Marakalala designed a study to test whether these proteins drive the lung damage seen in TB. The researchers focused on macrophage-driven signaling through ALOX5 and LTA4H, molecules implicated in inflammatory metabolism. Using tissue-level analyses alongside laboratory and animal experiments, they set out to link specific host pathways to the severe pulmonary immunopathology that can follow TB and to test whether those pathways can be interrupted to reduce harm.

To explore the connection between host enzymes and TB lung damage, the team used immune-histopathological assays to look for patterns of inflammation and tissue change in infected lungs. These assays demonstrated an association of macrophage driven ALOX5 signaling with severe pulmonary immunopathology during TB. Complementing the tissue work, the group ran both in vitro and in vivo assays to directly test how ALOX5 signaling contributes to granulomatous inflammation—the clustering of immune cells that characterizes TB lesions. The experimental data showed that ALOX5-driven pathways promote TB-induced granulomatous inflammation. Importantly, the researchers intercepted this signaling pathway with clinically approved pharmaceutical inhibitors and observed reduced lung damage during disease. As the lung pathology improved, there was also an accompanying increase in bactericidal activity, suggesting that limiting this host-driven inflammation can both protect tissue and support bacterial control.

Taken together, the findings point to macrophage-driven inflammation via ALOX5 (and related LTA4H activity) as a modifiable contributor to TB-induced lung injury. The study supports the idea that host-directed strategies aimed at these pathways could prevent or reduce the destructive granuloma caseation and chronic pulmonary immunopathology that many TB survivors experience. Because the pathway was blocked with clinically approved pharmaceutical inhibitors in the experiments, the work raises the possibility of repurposing existing drugs or fast-tracking new agents that target ALOX5/LTA4H signaling. Such an approach could complement antibiotic regimens by protecting lung tissue, improving bactericidal outcomes, and ultimately reducing long-term respiratory disability in people affected by TB. The authors conclude that targeting ALOX5-driven macrophage inflammation warrants further development as a therapeutic strategy to prevent exacerbated TB-associated lung damage.